Back to Stocks

TIVC

Tivic Health Systems, Inc.
1 filings tracked
healthcarebiotechnologyMICRO (<$300M)

Company Intelligence Hub

Filing history, signal momentum, and bull/bear evolution

Chronological Filing Evolution (Click to filter / toggle)

Thesis (Bull Case Evolution)

Tivic Health has completed a comprehensive corporate metamorphosis, transitioning from a consumer healthtech company to a focused biopharmaceutical entity.…

Bullish Outlook

Antithesis (Bear Case / Structural Risks)

Despite the strategic pivot, Tivic Health faces a precarious financial situation, as evidenced by a formal 'going concern' warning from its auditors. The company is currently pre-revenue, burning through cash at a rate that threatens its survival within twelve months.…

Risk Factors

Read the full bull/bear analysis

You are reading the free preview. Start a free trial to unlock the complete bull & bear analysis for every TIVC filing.

Start Free Trial

Synthesis (Verdict & Resolution)

Tivic Health represents a classic asymmetric biotech bet: a high-risk, high-reward pivot into the biodefense sector. The filing confirms that the legacy consumer business has been successfully amputated, leaving a clean but fragile slate. The success of the company now hinges entirely on the regulatory and procurement path of Entolimod. If the company can leverage its domestic manufacturing and FDA designations to secure BARDA or DoD contracts, the operating leverage will be explosive. However, the window for execution is narrow. The combination of a 'going concern' qualification, significant lease liabilities, and the threat of Nasdaq delisting creates a high-pressure environment. Investors are essentially weighing the scientific validity of the TLR5 agonist and the strategic value of the San Antonio facility against a balance sheet that is heavily leveraged and prone to extreme dilution.

Selected Quarter

Core Takeaway

Tivic has successfully removed the drag of its consumer business but now faces a race against time to secure government contracts before its cash runway expires.

Investor Lens

The trade-off is between the high-ceiling potential of a government biodefense monopoly and the high-probability risk of bankruptcy or extreme dilution.

Watch Next

Nasdaq bid price compliance by September 15, 2026, and any BARDA/DoD funding announcements.

View Full SEC Report

Signal Momentum Chart

Quarterly net bull/bear signal ratio. Click nodes to select a quarter.

BULLISH (+1.0)NEUTRAL (0.0)BEARISH (-1.0)+0.24Q1 '26 (10-K)

Signal Timeline

Active Filters:Quarter: Q1 '26 (10-K)
bullishMar 30

Appointment of biopharma veteran Michael Handley as CEO to lead the Entolimod pivot.

management change
70%
bullishMar 30

Complete exit from the cash-burning ClearUP consumer health business.

divestiture
60%
bullishMar 30

Acquired Scorpius assets to establish Velocity Bioworks, vertically integrating manufacturing.

acquisition
80%
bearishMar 30

Significant dilution risk from $16.25M convertible note with a $0.39 floor price.

dilution risk
90%
neutralMar 30

Secured $50M equity line with Tumim Stone to extend operational runway.

capital raise
50%

Filing History

10-KMar 30, 2026
Expand Sequence

Tivic Health represents a classic asymmetric biotech bet: a high-risk, high-reward pivot into the biodefense sector. The filing confirms that the legacy consumer business has been successfully amputated, leaving a clean but fragile slate. The success of the company now hinges entirely on the regulatory and procurement path of Entolimod. If the company can leverage its domestic manufacturing and FDA designations to secure BARDA or DoD contracts, the operating leverage will be explosive. However, the window for execution is narrow. The combination of a 'going concern' qualification, significant lease liabilities, and the threat of Nasdaq delisting creates a high-pressure environment. Investors are essentially weighing the scientific validity of the TLR5 agonist and the strategic value of the San Antonio facility against a balance sheet that is heavily leveraged and prone to extreme dilution.

Disclaimer: The synthesis provided is generated by AI models and should not be construed as investment advice. Analysis is based solely on regulatory data present at the time of publication. Consult a financial advisor for specific investment strategies.